progression

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. People…

Overachieving is my jam. Go big or go home. I strive to be the best at whatever it is I do. Currently, I am achieving greatness in my ability to fall. Three falls in three weeks is a new record. The first one happened in the kitchen. Upon feeling myself…

“If I were you two, I think I’d plan for the worst,” Amy, my physiatrist, said to my wife and me as we sat in the examination room. It was just after 11 a.m. on Friday, Jan. 18. January has become one of two pivotal months in terms of…

One of the hardest things I’ve had to accept with MS is the necessity of asking for help. Pride and self-reliance dissipate remarkably quickly when you find yourself splayed on the floor and you no longer have the capacity to get up. In extremis, I then ask for help.

Age at disease onset, number of early relapses, and the extent of brain damage at baseline can help identify those who are at high risk of progression from relapsing-remitting multiple sclerosis into the secondary progressive phase of the disease, a new study shows. The study with that finding, “…

Siponimod (BAF312) reduces the risk of disability progression in patients with secondary progressive multiple sclerosis (SPMS), a Phase 3 clinical trial shows. An article about the Novartis therapy’s trial results appeared in the journal The Lancet. The title is “Siponimod versus placebo in secondary progressive multiple sclerosis…

I have been contemplative these last few days, lost in thought regarding the state of the MS. I am not sad or upset, simply in observation mode. Reaching for what may have precipitated this gentle melancholy, I realize I am on the precipice of my 49th year. While MS continues…

Cladribine tablets reduce the risk of disability progression and relapse in patients with relapsing multiple sclerosis (MS), the CLARITY clinical trial indicates. The treatment was also well-tolerated and had a good safety profile, according to a presentation at the Annual Meeting of the American Academy of Neurology (AAN) in Boston,…

Research from Indiana University School of Medicine showed that D3T – a compound that triggers copying of antioxidant genes and production of the antioxidant glutathione – delays disease development and lowers disease severity in experimental autoimmune encephalomyelitis (EAE) animal models. The models mimicked multiple sclerosis (MS) in humans, advancing further exploration…